Overview

This trial is active, not recruiting.

Conditions liver transplantation, immunosuppression
Treatment extracorporeal photopheresis procedure (fec)
Phase phase 1/phase 2
Sponsor Red de Terapia Celular
Collaborator Spanish National Health System
Start date April 2013
End date June 2016
Trial size 10 participants
Trial identifier NCT01824368, 2012-000633-39, FEC-TH

Summary

The purpose of this study is to evaluate the safety of extracorporeal photopheresis in patients with long-standing liver transplantation subjected to a progressive reduction of immunosuppression by complications arising from its use.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
People with liver transplantation over 2 years following treatment with immunosuppression including cyclosporine or tacrolimus.
extracorporeal photopheresis procedure (fec)
The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral. 1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation. Finally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex.

Primary Outcomes

Measure
adverse event rate and rate of transplant rejection
time frame: 1 year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Have been receiving liver transplant two years ago. - Be 18 years or older. - Treatment with immunosuppression including cyclosporine or tacrolimus. - Having a normal liver function in the last year - Not have suffered acute rejection in the last year and have no chronic rejection - Submit any significant side effects from medication immunosuppressive (hypertension, creatinine greater than 1.7 mgDl, diabetes, morbid obesity, osteoporosis, hyperlipidemia, severe hirsutism, neurotoxicity novo malignancy, etc.) - Etiology of underlying disease: alcoholic cirrhosis with or without hepatocarcinoma, metabolic diseases, amyloidotic polyneuropathy family, biliary atresia, fulminant hepatitis non-A, non-B, non-C, cirrhosis cryptogenic and generally causes no viral or autoimmune. - Patients offering sufficient guarantees of adherence to protocol - Patients who give written informed consent for participate in the study. - It is necessary that the patient meets all inclusion criteria. Exclusion Criteria: - Underlying disease of the autoimmune (primary sclerosing cholangitis, autoimmune cirrhosis, primary biliary cirrhosis) or epatocarcinoma about cirrhosis of viral or autoimmune. - Patients with chronic rejection, or acute rejection in the last year. - Patients with liver retransplantation. - patients with history of hypersensitivity or idiosyncratic reactions to methoxsalen, psoralen the compounds or any of the excipients. - patients with melanoma, cutaneous basal cell carcinoma or squamous cell coexistent. - Patients with aphakia. - Patients taking Oxoralen. - Pregnant women or nursing mothers, or adults of childbearing age not using effective contraception. - Participation in another clinical trial. - Inability to understand informed consent.

Additional Information

Official title FOTOAFERESIS EXTRACORPÓREA EN EL TRASPLANTE HEPÁTICO. ENSAYO CLINICO EN FASE II DE SEGURIDAD Y EFICACIA EN PACIENTES CON RETIRADA PROGRESIVA DE LA INMUNOSUPRESIÓN
Trial information was received from ClinicalTrials.gov and was last updated in September 2015.
Information provided to ClinicalTrials.gov by Red de Terapia Celular.